Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8700 | 0.78 | — | — | |
| SCHEMBL23766 | 0.68 | — | — | |
| SCHEMBL1162618 | 0.68 | — | — | |
| SCHEMBL3101816 | 0.63 | TRPA1 (0.42) | CA1CA2TSHRPARP1TRPA1 | |
| Indene SCHEMBL1162574 | 0.63 | — | — | |
| Indene SCHEMBL8336138 | 0.63 | CA1 (0.55) | CA1CA2TSHRPARP1TRPA1 | |
| Indene SCHEMBL29350094 | 0.63 | — | — | |
| Indene SCHEMBL8617 | 0.63 | — | — | |
| SCHEMBL2680 | 0.63 | — | — | |
| SCHEMBL4131378 | 0.62 | CA1 (0.44) | CA1CA2PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148551-B2 | Tricyclic aromatics and liquid-crystalline medium | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2012-04-03 | — | — | US | disclosed |
| US-8029696-B2 | Fused naphthalenes | MERCK PATENT GMBH (DE) | 2011-10-04 | — | — | US | disclosed |
| US-20110034469-A1 | Heterocyclic Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-10 | — | — | US | disclosed |
| WO-2011016576-A1 | ALANINE DERIVATIVES AS INHIBITORS OF APOPTOSIS PROTEINS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-10 | — | — | WO | disclosed |
| US-20100059711-A1 | FUSED NAPHTHALENES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-03-11 | — | — | US | disclosed |
| US-20090131689-A1 | TRICYCLIC AROMATICS AND LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034469-A1 | Heterocyclic Compound | BIRC5, XIAP, BIRC2 | CA1 417/4885CA2 341/4885TSHR 3703/4885 |
| US-20090131689-A1 | TRICYCLIC AROMATICS AND LIQUID-CRYSTALLINE MEDIUM | CHRM1, C1S, CHRM2 | CA1 831/4885CA2 848/4885TSHR 959/4885 |
| US-20100059711-A1 | FUSED NAPHTHALENES | CCNE2, CCNE1, F12 | CA1 901/4885CA2 1631/4885TSHR 3482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.